Literature DB >> 8926085

Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908.

E M Barry1, O Gomez-Duarte, S Chatfield, R Rappuoli, M Pizza, G Losonsky, J Galen, M M Levine.   

Abstract

Salmonella typhi vaccine strain CVD 908 can deliver heterologous antigens to the host immune system following mucosal immunization. Stable expression of foreign proteins in Salmonella cells often requires antigen-specific engineering strategies. Fusion of antigens to stabilizing proteins has proven to be a successful strategy for rescuing otherwise unstable proteins. We designed plasmids to allow the fusion of antigens to the amino terminus or carboxyl terminus of fragment C of tetanus toxin, separated by a 4-amino-acid hinge region. Towards the ultimate goal of developing a live oral diphtheria-pertussis-tetanus vaccine, we used these plasmids to stably express the S1 subunit of pertussis toxin in CVD 908. Driven by the anaerobically inducible nirB promoter, the S1 subunit alone was expressed poorly in Salmonella cytoplasm. In contrast, hybrid proteins with S1 fused to either the amino or carboxyl terminus of fragment C were expressed at a high level in CVD 908 and were recognized in Western blot (immunoblot) analysis by monoclonal antibodies directed to S1 and to fragment C. Mice were immunized by the oral or intranasal routes with CVD 908 derivatives harboring these recombinant plasmids. All fusion proteins elicited serum antibody responses to fragment C following intranasal immunization, whereas oral inoculation did not. The configuration of antigens constituting the fusion was critical; S1 fused to the amino terminus of fragment C was less effective than S1 fused to the carboxyl terminus in generating anti-fragment C antibodies. CVD 908 expressing truncated S1 fused to the carboxyl terminus of fragment C elicited neutralizing serum pertussis antitoxin following intranasal immunization of mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8926085      PMCID: PMC174353          DOI: 10.1128/iai.64.10.4172-4181.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Monoclonal antibodies to pertussis toxin: utilization as probes of toxin function.

Authors:  J G Kenimer; K J Kim; P G Probst; C R Manclark; D G Burstyn; J L Cowell
Journal:  Hybridoma       Date:  1989-02

2.  Location and sequence of the promoter of the gene for the NADH-dependent nitrite reductase of Escherichia coli and its regulation by oxygen, the Fnr protein and nitrite.

Authors:  P S Jayaraman; T C Peakman; S J Busby; R V Quincey; J A Cole
Journal:  J Mol Biol       Date:  1987-08-20       Impact factor: 5.469

3.  Pertussis toxin gene: nucleotide sequence and genetic organization.

Authors:  C Locht; J M Keith
Journal:  Science       Date:  1986-06-06       Impact factor: 47.728

Review 4.  Virulence factors of Bordetella pertussis.

Authors:  A A Weiss; E L Hewlett
Journal:  Annu Rev Microbiol       Date:  1986       Impact factor: 15.500

5.  Mutational analysis of the nucleotide sequence at the FNR-dependent nirB promoter in Escherichia coli.

Authors:  P S Jayaraman; J A Cole; S J Busby
Journal:  Nucleic Acids Res       Date:  1989-01-11       Impact factor: 16.971

6.  Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections.

Authors:  H Sato; A Ito; J Chiba; Y Sato
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

7.  The A protomer of islet-activating protein, pertussis toxin, as an active peptide catalyzing ADP-ribosylation of a membrane protein.

Authors:  T Katada; M Tamura; M Ui
Journal:  Arch Biochem Biophys       Date:  1983-07-01       Impact factor: 4.013

8.  A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells.

Authors:  M Tamura; K Nogimori; M Yajima; K Ase; M Ui
Journal:  J Biol Chem       Date:  1983-06-10       Impact factor: 5.157

9.  Staphylococcus aureus-stimulated human mononuclear leucocyte-conditioned medium augments the basal and stimuli-induced neutrophil respiratory burst and degranulation.

Authors:  A Ferrante; M Nandoskar; E J Bates; D H Goh
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

Review 10.  Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system.

Authors:  G Dougan; C E Hormaeche; D J Maskell
Journal:  Parasite Immunol       Date:  1987-03       Impact factor: 2.280

View more
  16 in total

1.  Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA.

Authors:  J E Galen; J Nair; J Y Wang; S S Wasserman; M K Tanner; M B Sztein; M M Levine
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM(197), and its fragments in Salmonella typhi vaccine strain CVD 908-htrA.

Authors:  N Orr; J E Galen; M M Levine
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

3.  Expression of a C terminally truncated form of pertussis toxin S1 subunit effectively induces protection against pertussis toxin following DNA-based immunization.

Authors:  Kazunari Kamachi; Yoshichika Arakawa
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

4.  Fusion expression and immunogenicity of Bordetella pertussis PTS1-FHA protein: implications for the vaccine development.

Authors:  Zhang Jinyong; Zhang Xiaoli; Zhang Weijun; Guo Ying; Guo Gang; Mao Xuhu; Zou Quanming
Journal:  Mol Biol Rep       Date:  2010-09-28       Impact factor: 2.316

5.  Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis Bacillus Calmette-Guérin producing a pertussis toxin-tetanus toxin hybrid protein.

Authors:  B Abomoelak; K Huygen; L Kremer; M Turneer; C Locht
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

6.  Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.

Authors:  C O Tacket; M B Sztein; S S Wasserman; G Losonsky; K L Kotloff; T L Wyant; J P Nataro; R Edelman; J Perry; P Bedford; D Brown; S Chatfield; G Dougan; M M Levine
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice.

Authors:  I P Nascimento; W O Dias; R P Mazzantini; E N Miyaji; M Gamberini; W Quintilio; V C Gebara; D F Cardoso; P L Ho; I Raw; N Winter; B Gicquel; R Rappuoli; L C Leite
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

8.  Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains.

Authors:  O G Gómez-Duarte; M F Pasetti; A Santiago; M B Sztein; S L Hoffman; M M Levine
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

9.  Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica Serovar Typhi elicits full immune response by intranasal vaccination.

Authors:  Fengling Luo; Yong Feng; Min Liu; Pingfei Li; Qin Pan; Victor Tunje Jeza; Bing Xia; Jianguo Wu; Xiao-Lian Zhang
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

10.  Salmonella enterica serovar Typhi live vector vaccines delivered intranasally elicit regional and systemic specific CD8+ major histocompatibility class I-restricted cytotoxic T lymphocytes.

Authors:  Marcela F Pasetti; Rosangela Salerno-Gonçalves; Marcelo B Sztein
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.